Amundi Has $1.43 Billion Stake in Thermo Fisher Scientific Inc. $TMO

Key Points

• Amundi increased its stake in Thermo Fisher Scientific by 5.9%, acquiring an additional 168,197 shares, bringing its total holdings to over 3 million shares, valued at approximately $1.43 billion.
• CEO Marc N. Casper sold 10,000 shares for around $5 million, reducing his ownership by 7.99%, while institutional investors hold 89.23% of the company’s stock.
• Equity analysts have adjusted price targets for Thermo Fisher Scientific, with a consensus target of $593.00 and a rating of "Moderate Buy" based on recent performance and estimates for the fiscal year.

Amundi raised its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 5.9% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,029,044 shares of the medical research company's stock after buying an additional 168,197 shares during the quarter. Amundi owned 0.80% of Thermo Fisher Scientific worth $1,426,316,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the company. Bernard Wealth Management Corp. purchased a new position in Thermo Fisher Scientific during the 4th quarter worth approximately $25,000. Ameriflex Group Inc. acquired a new stake in shares of Thermo Fisher Scientific in the fourth quarter worth $30,000. Keystone Global Partners LLC purchased a new position in shares of Thermo Fisher Scientific during the first quarter valued at $31,000. IMA Advisory Services Inc. purchased a new stake in Thermo Fisher Scientific in the 1st quarter worth about $35,000. Finally, Smallwood Wealth Investment Management LLC acquired a new stake in Thermo Fisher Scientific during the 1st quarter worth about $37,000. Institutional investors and hedge funds own 89.23% of the company's stock.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the company's stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the transaction, the chief executive officer owned 115,174 shares of the company's stock, valued at approximately $57,697,567.04. This represents a 7.99% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Gianluca Pettiti sold 400 shares of the firm's stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the transaction, the executive vice president owned 22,367 shares in the company, valued at approximately $10,735,712.66. This represents a 1.76% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 29,666 shares of company stock valued at $13,982,763. Insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Price Performance

Thermo Fisher Scientific stock traded up $2.71 during trading hours on Friday, hitting $492.20. 1,442,575 shares of the stock were exchanged, compared to its average volume of 1,624,930. The stock has a market capitalization of $185.86 billion, a P/E ratio of 28.47, a P/E/G ratio of 2.61 and a beta of 0.75. The business's 50-day moving average is $460.72 and its two-hundred day moving average is $453.43. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The business had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. During the same period in the previous year, the business earned $5.37 EPS. Thermo Fisher Scientific's revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Equities research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 0.3%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 9.95%.

Analyst Upgrades and Downgrades

TMO has been the topic of several research reports. Wells Fargo & Company dropped their price objective on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating on the stock in a research note on Thursday, July 24th. UBS Group increased their price target on Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a "neutral" rating in a report on Thursday, July 24th. Evercore ISI dropped their price objective on Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a research note on Tuesday, July 8th. Wall Street Zen raised shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research report on Saturday, August 30th. Finally, Royal Bank Of Canada set a $561.00 target price on shares of Thermo Fisher Scientific and gave the company an "outperform" rating in a research report on Tuesday. Sixteen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $589.38.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.